Moderna shares fall despite promising data from cancer vaccine trial
Moderna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.
Read MoreModerna's mRNA vaccine, when combined with Merck's blockbuster drug Keytruda, showed promise in treating melanoma, a kind of skin cancer.
Read MoreModerna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer Source link
Read MoreCarMax soared on the back of better-than-expected quarterly earnings. Source link
Read MoreDeutsche Bank upgraded Catalent on Monday to buy from hold as the company's partnership with Moderna could help it grow
Read MoreModerna's chief medical officer said advancements in mRNA technology since the outset of the Covid pandemic have ushered in a
Read MoreModerna shares closed nearly 7% after TD Cowen upgraded the stock, saying the company will "be a leader" in the
Read MoreNames on the move ahead of the open. Source link
Read MoreHere are the biggest calls on Wall Street on Source link
Read MoreNvidia shares spiked, while Domino's Pizza dropped. Source link
Read More